Jeffrey Heier Sells 3,057 Shares of Ocular Therapeutix (NASDAQ:OCUL) Stock

Ocular Therapeutix, Inc. (NASDAQ:OCUL) insider Jeffrey Heier sold 3,057 shares of the stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $8.28, for a total transaction of $25,311.96. Following the sale, the insider owned 323,368 shares of the company’s stock, valued at $2,677,487.04. This trade represents a 0.94% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Ocular Therapeutix Price Performance

OCUL stock traded up $0.55 during midday trading on Wednesday, reaching $9.50. 7,845,017 shares of the company’s stock traded hands, compared to its average volume of 7,060,435. The company has a 50-day simple moving average of $10.53 and a two-hundred day simple moving average of $11.62. The company has a quick ratio of 15.32, a current ratio of 15.39 and a debt-to-equity ratio of 0.11. The company has a market cap of $2.07 billion, a price-to-earnings ratio of -6.60 and a beta of 0.90. Ocular Therapeutix, Inc. has a 1-year low of $5.78 and a 1-year high of $16.44.

Ocular Therapeutix (NASDAQ:OCUL) last issued its quarterly earnings results on Thursday, February 5th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.04. The business had revenue of $13.25 million for the quarter, compared to analyst estimates of $16.13 million. Ocular Therapeutix had a negative return on equity of 70.68% and a negative net margin of 511.90%.The firm’s revenue for the quarter was down 22.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.29) earnings per share. On average, analysts anticipate that Ocular Therapeutix, Inc. will post -0.98 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts have recently issued reports on OCUL shares. Needham & Company LLC decreased their price target on shares of Ocular Therapeutix from $20.00 to $18.00 and set a “buy” rating for the company in a report on Friday, February 20th. TD Cowen reiterated a “buy” rating on shares of Ocular Therapeutix in a report on Thursday, October 30th. Wall Street Zen raised Ocular Therapeutix from a “sell” rating to a “hold” rating in a research note on Saturday, February 7th. Chardan Capital reaffirmed a “buy” rating and set a $21.00 price target on shares of Ocular Therapeutix in a research report on Wednesday, February 18th. Finally, HC Wainwright lifted their price objective on Ocular Therapeutix from $19.00 to $21.00 and gave the company a “buy” rating in a report on Monday, December 8th. Twelve equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $23.78.

Institutional Investors Weigh In On Ocular Therapeutix

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Steward Partners Investment Advisory LLC grew its holdings in shares of Ocular Therapeutix by 124.2% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 2,242 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 1,242 shares in the last quarter. Nisa Investment Advisors LLC raised its holdings in Ocular Therapeutix by 62.9% during the second quarter. Nisa Investment Advisors LLC now owns 3,604 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 1,392 shares in the last quarter. Hilton Head Capital Partners LLC acquired a new position in Ocular Therapeutix during the fourth quarter valued at approximately $42,000. Atlas Capital Advisors Inc. bought a new position in Ocular Therapeutix in the fourth quarter valued at approximately $61,000. Finally, KBC Group NV acquired a new position in shares of Ocular Therapeutix during the 4th quarter worth approximately $78,000. 59.21% of the stock is owned by institutional investors.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.